PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 6, 2026Journal of Medical Case Reports0 citationsOpen Access

Effectiveness of neoadjuvant chemotherapy with lenvatinib plus pembrolizumab in advanced endometrial cancer: a case report

KKKatsuyuki KonnaiHFHiroyuki FujiwaraTNTsuguto Notomi

Key Points

  • This research investigates the effectiveness of lenvatinib and pembrolizumab as neoadjuvant therapy in advanced endometrial cancer.
  • Administered neoadjuvant chemotherapy using lenvatinib and pembrolizumab
  • Monitored tumor size and surgical outcomes
  • Assessed pathological response post-surgery
  • Achieved significant tumor regression prior to surgery
  • Enabled complete surgical resection of tumors
  • Resulted in a pathological complete response in the report case

Abstract

Lenvatinib plus pembrolizumab may represent a feasible neoadjuvant option for achieving tumor regression and enabling surgical resection with a pathological complete response in advanced endometrial cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Konnai et al. (2026) studied this question.

synapsesocial.com/papers/69aa6f3c531e4c4a9ff595a8https://doi.org/10.1186/s13256-026-05920-4
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden2024
  2. 2Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights2025
  3. 3Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-7752026 · 1 citations
  4. 4#88 Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: primary results of the phase 3 ENGOT-en9/LEAP-001 study2024 · 8 citations
  5. 5Efficacy of lenvatinib plus pembrolizumab for recurrent endometrial cancer: a focus on the nonendometrioid histology including carcinosarcoma2026